Department of Internal Medicine B, University Hospital Greifswald, Friedrich-Loeffler-Strasse 23 a, D-17475 Greifswald, Germany.
Crit Care. 2010;14(6):R223. doi: 10.1186/cc9367. Epub 2010 Dec 10.
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), the major endothelial receptor for oxidized low-density lipoprotein, is also involved in leukocyte recruitment. Systemic leukocyte activation in sepsis represents a crucial factor in the impairment of the microcirculation of different tissues, causing multiple organ failure and subsequently death. The aim of our experimental study was to evaluate the effects of LOX-1 inhibition on the endotoxin-induced leukocyte adherence and capillary perfusion within the intestinal microcirculation by using intravital microscopy (IVM).
We used 40 male Lewis rats for the experiments. Ten placebo-treated animals served as a control. Thirty animals received 5 mg/kg lipopolysaccharide (LPS) intravenously. Ten endotoxemic rats remained untreated. In 10 LPS animals, we administered additionally 10 mg/kg LOX-1 antibodies. Ten further LPS animals received a nonspecific immunoglobulin (rat IgG) intravenously. After 2 hours of observation, intestinal microcirculation was evaluated by using IVM; the plasma levels of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-α) were determined; and LOX-1 expression was quantified in intestinal tissue with Western blot and reverse-transcription polymerase chain reaction (PCR).
LOX-1 inhibition significantly reduced LPS-induced leukocyte adhesion in intestinal submucosal venules (P < 0.05). At the protein and mRNA levels, LOX-1 expression was significantly increased in untreated LPS animals (P < 0.05), whereas in animals treated with LOX-1 antibody, expression of LOX-1 was reduced (P < 0.05). MCP-1 plasma level was reduced after LOX-1 antibody administration.
Inhibition of LOX-1 reduced leukocyte activation in experimental endotoxemia. LOX-1 represents a novel target for the modulation of the inflammatory response within the microcirculation in sepsis.
凝集素样氧化型低密度脂蛋白受体-1(LOX-1)是氧化型低密度脂蛋白的主要内皮受体,也参与白细胞募集。脓毒症中的全身白细胞激活是不同组织微循环受损的关键因素,导致多器官衰竭,进而导致死亡。我们的实验研究旨在通过活体显微镜检查(IVM)评估 LOX-1 抑制对内毒素诱导的白细胞黏附和肠微循环毛细血管灌注的影响。
我们使用 40 只雄性 Lewis 大鼠进行实验。10 只接受安慰剂治疗的动物作为对照。30 只动物接受静脉内 5mg/kg 脂多糖(LPS)。10 只内毒素血症动物未接受治疗。在 10 只 LPS 动物中,我们另外给予 10mg/kg LOX-1 抗体。另外 10 只 LPS 动物接受静脉内非特异性免疫球蛋白(大鼠 IgG)。观察 2 小时后,通过 IVM 评估肠道微循环;测定单核细胞趋化蛋白-1(MCP-1)和肿瘤坏死因子-α(TNF-α)的血浆水平;并通过 Western blot 和逆转录聚合酶链反应(PCR)定量肠道组织中的 LOX-1 表达。
LOX-1 抑制显著降低了 LPS 诱导的肠黏膜下小静脉白细胞黏附(P<0.05)。在未治疗的 LPS 动物中,LOX-1 表达在蛋白质和 mRNA 水平上均显著增加(P<0.05),而在接受 LOX-1 抗体治疗的动物中,LOX-1 表达减少(P<0.05)。LOX-1 抗体给药后 MCP-1 血浆水平降低。
LOX-1 抑制降低了实验性内毒素血症中的白细胞激活。LOX-1 是脓毒症微循环中炎症反应调节的新靶点。